scholarly journals 60P Real-life use of Oncotype DX Breast Recurrence Score® test for the management of patients with node-negative and node-positive breast cancer in the autonomous community of Galicia (Spain)

2021 ◽  
Vol 32 ◽  
pp. S46
Author(s):  
I. Fernandez-Perez ◽  
S. Antolin Novoa ◽  
L. De Paz Arias ◽  
L. Vazquez Tuñas ◽  
M.E. Perez Lopez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Real Life ◽  
Recurrence Score ◽  
Oncotype Dx ◽  
Autonomous Community ◽  
Node Negative ◽  
Node Positive ◽  
Breast Recurrence ◽  
Positive Breast Cancer

Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 11052-11052 ◽  
Author(s):  
Frederique Madeleine Penault-Llorca ◽  
Thomas Filleron ◽  
Bernard Asselain ◽  
Frederick L. Baehner ◽  
Pierre Fumoleau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Recurrence Score ◽  
Oncotype Dx ◽  
Breast Cancer Patients ◽  
Node Positive ◽  
Oncotype Dx Recurrence Score ◽  
Positive Breast Cancer

scholarly journals Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer

2016 ◽  
Vol 34 (2) ◽  
pp. 130-138 ◽  
Author(s):  
Megan C. Roberts ◽  
Morris Weinberger ◽  
Stacie B. Dusetzina ◽  
Michaela A. Dinan ◽  
Katherine E. Reeder-Hayes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Black Women ◽  
Racial Disparities ◽  
Oncotype Dx ◽  
Phase Iii ◽  
Adjusted Relative Risk ◽  
Node Negative ◽  
Node Positive ◽  
Black Patients ◽  
Positive Breast Cancer

Purpose Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-making. ODX has the potential to improve quality of care; however, if not equally accessible across racial groups, disparities in cancer care quality may persist or worsen. We examined racial disparities in ODX testing uptake. Methods We used data from the Carolina Breast Cancer Study, phase III, a longitudinal, population-based study of 2,998 North Carolina women who received a diagnosis of breast cancer between 2008 and 2014. Our primary analysis used modified Poisson regression to determine the association between race and whether ODX testing was ordered among two strata: node-negative and node-positive breast cancer. Results A total of 1,468 women with estrogen receptor–positive, human epidermal growth factor receptor-2–negative, stage I or II breast cancer met inclusion criteria. Black patients had higher-grade and larger tumors, more comorbidities, younger age at diagnosis, and lower socioeconomic status than non-black women. Overall, 42% of women had ODX test results in their pathology reports. Compared with those who did not receive ODX testing, women who received ODX testing tended to be younger and have medium tumor size and grade. Our regression analyses indicated no racial disparities in ODX uptake among node-negative patients. However, racial differences were detected among node-positive patients, with black patients being 46% less likely to receive ODX testing than non-black women (adjusted relative risk, 0.54; 95% CI, 0.35 to 0.84; P = .006). Conclusion We did not find racial disparities in ODX testing for node-negative patients for whom ODX testing is guideline recommended and widely covered by insurers. However, our findings suggest that a newer, non–guideline-concordant application of ODX testing for node-positive breast cancer was accessed less by black women than by non-black women, reflecting more guideline concordant care among black women.

scholarly journals Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer

2019 ◽  
Vol 26 (1) ◽  
pp. 101-109
Author(s):  
Fei Wang ◽  
Sonya Reid ◽  
Wei Zheng ◽  
Tuya Pal ◽  
Ingrid Meszoely ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Recurrence Score ◽  
Oncotype Dx ◽  
Er Positive ◽  
Sex Disparity ◽  
Breast Recurrence ◽  
Positive Breast Cancer

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer

2012 ◽  
Vol 133 (3) ◽  
pp. 1115-1123 ◽  
Author(s):  
Nathan W. D. Lamond ◽  
Chris Skedgel ◽  
Daniel Rayson ◽  
Lynn Lethbridge ◽  
Tallal Younis
Keyword(s):  
Breast Cancer ◽  
Recurrence Score ◽  
Cost Utility ◽  
Node Negative ◽  
Node Positive ◽  
Positive Breast Cancer

Axillary Reverse Mapping: A Prospective Study in Women with Clinically Node Negative and Node Positive Breast Cancer

2013 ◽  
Vol 20 (10) ◽  
pp. 3303-3307 ◽  
Author(s):  
Carol Connor ◽  
Marilee McGinness ◽  
Joshua Mammen ◽  
Lori Ranallo ◽  
Stephanie LaFaver ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prospective Study ◽  
Node Negative ◽  
Axillary Reverse Mapping ◽  
Node Positive ◽  
A Prospective Study ◽  
Reverse Mapping ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document